Oftan Akvakol (Chloramphenicol)

Chloramphenicol blocks bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide‑bond formation. This bacteriostatic action stops the growth of susceptible Gram‑positive and Gram‑negative organisms that cause ocular infections.

The dosing regimen for Oftan Akvakol is determined by the prescribing clinician based on the type and severity of the infection, patient age and response to therapy. The prescriber will specify the number of drops and frequency.

Topical chloramphenicol is generally considered low risk because systemic absorption is minimal, but it should be used only if clearly needed and after risk‑benefit assessment by a healthcare professional. Consultation with a physician is advised.

Submit an enquiry on the product page at gnhindia.com, providing the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then replies with pricing, availability, shipping details and any necessary import documentation.

Compared with fluoroquinolone eye drops, chloramphenicol offers a broad spectrum against both Gram‑positive and Gram‑negative bacteria and is bacteriostatic rather than bactericidal. It is often chosen for its efficacy in low‑resource settings, though resistance patterns and safety profiles differ.

Store the ophthalmic solution at temperatures below 25 °C, in its original container, protected from light and moisture. Do not freeze the product, and keep the cap tightly closed when not in use.

The solution is applied topically to the affected eye(s) as directed by the prescriber, typically using a sterile dropper to place the recommended number of drops onto the conjunctival sac, avoiding contact with the eyelid or lashes.

Serious adverse events, though rare, include severe allergic reactions such as anaphylaxis, corneal ulceration, and systemic bone‑marrow suppression if significant absorption occurs. Immediate medical attention is required if these symptoms develop.

Patients with a known hypersensitivity to chloramphenicol or any component of the formulation should avoid its use. Caution is also advised for individuals with pre‑existing bone‑marrow disorders or those receiving systemic drugs that may interact adversely.